Stefani Spranger, Ph.D.

Dr. Stefani Spranger is an Assistant Professor at the Koch Institute for Integrative Cancer Research and the Department of Biology at the Massachusetts Institute of Technology. Dr. Spranger is widely regarded as an expert in cancer immunology and cancer biology. During her postdoctoral training at the University of Chicago, under the supervision of Dr. Thomas F. Gajewski, Dr. Spranger made the novel discovery that tumor cell-intrinsic activation of the oncogenic Wnt/ β-catenin pathway results the in exclusion of T cells from the tumor micro-environment. This groundbreaking work was published in Nature. In addition Dr. Spranger has co-authored significant scientific papers on key immunotherapeutic targets such as IDO, STING, Tregs and checkpoint inhibitors. She is the current chair of the ESC committee for SITC (Society for Immunotherapy of Cancer) and winner of the 2015 Wissler Fellowship Award at the University of Chicago.

Venn Therapeutics

3802 Spectrum Boulevard 

Suite 146

Tampa, FL 33612

  • LinkedIn
  • Twitter

© 2020 by Venn Therapeutics